The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...
Peter Guenter to retire as healthcare CEO, replaced by Danny Bar-Zohar; Matthias Heinzel steps down from life science unit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback